Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$947M |
| 2 |
Tesla
TSLA
|
+$608M |
| 3 |
Microsoft
MSFT
|
+$444M |
| 4 |
Accenture
ACN
|
+$409M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.06B |
| 2 |
Texas Instruments
TXN
|
+$1.92B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 4 |
Starbucks
SBUX
|
+$1.42B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1,000M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.52% |
| 2 | Financials | 7.13% |
| 3 | Consumer Discretionary | 6.46% |
| 4 | Healthcare | 5.43% |
| 5 | Communication Services | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3026
PUT
Kymera Therapeutics
KYMR
$8.51B
| $1.49M | ﹤0.01% |
+31,400
| New | +$1.39M |
|
3027
Fate Therapeutics
FATE
$286M
| $1.48M | ﹤0.01% |
424,277
+301,389
| +245% | +$1.17M |
|
3028
AnaptysBio
ANAB
$1.58B
| $1.48M | ﹤0.01% |
44,300
+23,926
| +117% | +$817K |
|
3029
ChargePoint
CHPT
$141M
| $1.48M | ﹤0.01% |
54,159
+24,872
| +85% | +$865K |
|
3030
Canadian Imperial Bank of Commerce
CM
$108B
| $1.48M | ﹤0.01% |
24,173
-719
| -3% | -$38.9K |
|
3031
TransAlta
TAC
$3.95B
| $1.48M | ﹤0.01% |
143,062
+105,562
| +281% | +$878K |
|
3032
Hackett Group
HCKT
$270M
| $1.48M | ﹤0.01% |
56,350
+37,695
| +202% | +$946K |
|
3033
IMAX
IMAX
$2.62B
| $1.48M | ﹤0.01% |
72,154
+52,436
| +266% | +$1.03M |
|
3034
Northrim BanCorp
NRIM
$590M
| $1.47M | ﹤0.01% |
82,756
+20,316
| +33% | +$333K |
|
|
TRTX
3035
TPG RE Finance Trust
TRTX
$612M
| $1.47M | ﹤0.01% |
172,718
+137,171
| +386% | +$1.2M |
|
3036
Midland States Bancorp
MSBI
$699M
| $1.46M | ﹤0.01% |
65,384
+23,242
| +55% | +$528K |
|
3037
PUT
Lithia Motors
LAD
$8.47B
| $1.46M | ﹤0.01% |
+4,600
| New | +$1.28M |
|
3038
Gray Television
GTN
$415M
| $1.46M | ﹤0.01% |
272,272
+145,263
| +114% | +$748K |
|
|
HSII
3039
DELISTED
Heidrick & Struggles
HSII
| $1.46M | ﹤0.01% |
37,476
+27,637
| +281% | +$999K |
|
3040
CALL
Melco Resorts & Entertainment
MLCO
$2.22B
| $1.45M | ﹤0.01% |
186,700
| – | – |
|
3041
Ardagh Metal Packaging
AMBP
$2.83B
| $1.45M | ﹤0.01% |
385,653
-52,222
| -12% | -$185K |
|
3042
Amerant Bancorp
AMTB
$1.16B
| $1.45M | ﹤0.01% |
67,916
+37,208
| +121% | +$817K |
|
3043
PUT
Keysight
KEYS
$54.5B
| $1.45M | ﹤0.01% |
+9,100
| New | +$1.3M |
|
3044
Mercantile Bank Corp
MBWM
$1.04B
| $1.44M | ﹤0.01% |
32,981
+16,423
| +99% | +$726K |
|
3045
Lemonade
LMND
$3.74B
| $1.44M | ﹤0.01% |
87,414
+65,144
| +293% | +$1.2M |
|
3046
CALL
Rapid7
RPD
$645M
| $1.44M | ﹤0.01% |
36,100
+21,100
| +141% | +$793K |
|
3047
Enliven Therapeutics
ELVN
$3.92B
| $1.44M | ﹤0.01% |
56,217
+42,012
| +296% | +$973K |
|
|
WBA
3048
PUT
DELISTED
Walgreens Boots Alliance
WBA
| $1.43M | ﹤0.01% |
+160,000
| New | +$1.65M |
|
3049
PUT
D.R. Horton
DHI
$40B
| $1.43M | ﹤0.01% |
+7,500
| New | +$1.32M |
|
3050
CALL
Agios Pharmaceuticals
AGIO
$1.79B
| $1.43M | ﹤0.01% |
32,200
| – | – |
|
Similar funds
Barclays's Q3 2024 Portfolio in Review
As of Q3 2024, Barclays held 5,593 positions worth $377B, up 15% from $327B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $31.3B of net new capital in Q3 2024, opening 785 new positions and adding to 2,954 existing holdings. Its largest new stake was Smurfit Westrock: 3,460,710 shares worth $171M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $2.06B trimmed.
- Barclays's largest Q3 2024 buy was Smurfit Westrock: 3,460,710 shares worth $171M.
- Barclays added most to iShares US Real Estate ETF in Q3 2024, an estimated $947M increase.
- Barclays's biggest Q3 2024 reduction was CRH, cutting an estimated $2.06B.
- Barclays fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $51.3M.
- Barclays's ten largest holdings make up 41% of its $377B portfolio in Q3 2024.
- Barclays opened 785 new positions and closed 322 in Q3 2024.
- Barclays's portfolio value rose 15% quarter-over-quarter to $377B.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.